BeiGene begins dosing in Phase II trial of BGB-3111 to treat MCL in China

Clinical-stage biopharmaceutical firm BeiGene has begun dosing in its Phase II clinical trial of BGB-3111 for the treatment of patients with mantle-cell lymphoma (MCL) in China.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news